BI Opens New $135-Million Manufacturing Facility for Respimat InhalerBy
Boehringer Ingelheim (BI) has opened a new production plant in Sant Cugat del Valles, Spain, to produce and package Respimat, an inhalation device for patients with asthma and chronic obstructive pulmonary disease (COPD).
BI invested more than EUR 120 million ($135 million) in the new 17,000-square-meter facility, and the expansion is expected to create up to 200 new jobs. The new plant includes space for production, laboratories, warehouse, offices, and technical areas. It will produce 25 million Respimat device units per year, which will account for more than one-half of the product’s global sales, to be exported to more than 100 countries, including Europe, the US, Japan, Mexico, Brazil, and Canada. The production equipment incorporates technology such as digitalization, system integration, robotics and automation.
The plant is expected to be operational at the end of 2019.
Source: Boehringer Ingelheim (Spanish website)